Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255804 | 0.89 | BCHE (0.50) | HPGDCYP1A2CYP2C19HTTMAPT | |
| SCHEMBL21819943 | 0.84 | MAOB (0.47) | — | |
| SCHEMBL21954259 | 0.84 | DYRK1A (0.49) | HPGDMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL30466627 | 0.84 | DYRK1A (0.49) | HPGDMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL30661687 | 0.84 | DYRK1A (0.47) | HPGDHTTKDM4AROCK2 | |
| SCHEMBL24964516 | 0.84 | DYRK1A (0.47) | HPGDHTTKDM4AROCK2 | |
| SCHEMBL20509355 | 0.83 | DYRK1A (0.48) | KDM4ARAB9A | |
| SCHEMBL17876425 | 0.83 | PTPN1 (0.48) | MAPTRAB9ANPC1 | |
| SCHEMBL5123403 | 0.83 | AKR1B1 (0.49) | KDM4A | |
| SCHEMBL24962449 | 0.83 | HDAC6 (0.52) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20210347748-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2021-11-11 | — | — | US | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| CN-107412788-A | The new compound being imaged for the Tau protein accumulated to intracerebral | 国立研究开发法人量子科学技术研究开发机构 | 2017-12-01 | — | — | CN | disclosed |
| CN-104736524-B | Novel compound for imaging Tau protein accumulated in brain | 国立研究开发法人量子科学技术研究开发机构 | 2017-06-23 | — | — | CN | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006022718-A1 | AKT3 COMPOSITIONS AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | HPGD 3025/4885CYP1A2 1451/4885CYP2C19 1957/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | HPGD 1284/4885CYP1A2 1551/4885CYP2C19 2771/4885 |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | HPGD 1496/4885CYP1A2 2356/4885CYP2C19 1225/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | HPGD 400/4885CYP1A2 35/4885CYP2C19 8/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | HPGD 3308/4885CYP1A2 1579/4885CYP2C19 2142/4885 |
| US-20210347748-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | INSR, INSRR, ARG1 | HPGD 956/4885CYP1A2 228/4885CYP2C19 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.